Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada approves SyntheMed's adhesion film

This article was originally published in Clinica

Executive Summary

REPEL-CV, SyntheMed's bioresorbable adhesion barrier film, has been approved in Canada for use in paediatric patients who undergo open heart surgery. The film is designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions – scar tissue that can cause the heart to attach to the sternum and other surrounding tissue surfaces. Hasselt, Belgium-based SyntheMed says it is intended to provide the therapeutic benefit and then degrade so that it is cleared from the body. REPEL-CV will be marketed throughout Canada by Force3 Medicale, a Montreal-based distributor of cardiac surgery products. It was CE marked for sale in Europe for use in all heart surgery patients in August 2006 (see Clinica No 1221, p 16). US FDA approval for use in paediatric patients is pending.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel